Alloy Therapeutics Launches RNA Delivery Platform to Target Diseases Beyond the Liver

0
14
Errik Anderson

BOSTON–Alloy Therapeutics has introduced TEMPER, a new small interfering RNA (siRNA) technology platform designed to improve the delivery of RNA-based therapies to tissues beyond the liver, including skeletal and cardiac muscle.

The Boston biotechnology company said the platform incorporates proprietary delivery technology obtained through a strategic transaction with Transcera, expanding its capabilities in RNA drug discovery and development.

TEMPER, which stands for Targeted Extra-Hepatic Modular Precision-Engineered RNA, combines siRNA design, specialized chemical modifications, and tissue-targeting technologies to support the development of genetic medicines.

RNA-based therapies have emerged as a promising approach to treating diseases by targeting the genetic instructions responsible for producing specific proteins. However, delivering these treatments to organs and tissues outside the liver remains a significant challenge.

While several siRNA therapies have demonstrated clinical success, their applications have largely focused on diseases involving the liver, where existing delivery technologies have been more effective.

Alloy’s new platform is intended to address these limitations by enabling researchers to target tissues that have historically been difficult to reach with RNA-based treatments.

“Targeted delivery is one of the most important opportunities in RNA medicines today, and we see tremendous potential to expand what is possible beyond the liver,” said Errik Anderson, Founder and Chief Executive Officer of Alloy Therapeutics.

“With TEMPER, we’re bringing together differentiated siRNA design and delivery technologies to help our partners pursue targets and tissues that have historically been difficult to reach. This is an important step in building the integrated RNA discovery capabilities needed to advance the next generation of genetic medicines.”

The platform uses proprietary lipid conjugate technology designed to improve the delivery of siRNA molecules to tissues outside the liver, particularly skeletal and cardiac muscle.

Its modular design also allows integration with other delivery technologies, including antibody-oligonucleotide conjugates, which combine antibodies with RNA-based molecules to direct treatments toward specific cells or tissues.

According to Alloy, these approaches could potentially expand RNA therapeutic delivery to the central nervous system and other organs.

The company plans to evaluate TEMPER’s ability to achieve tissue-specific delivery and functional gene silencing through preclinical studies.

These studies will assess whether the platform can deliver siRNA molecules to targeted tissues and reduce the expression of genes associated with disease.

“The liver was siRNA’s proving ground,” said Venkat Krishnamurthy, Chief Scientific Officer of Genetic Medicines at Alloy Therapeutics.

“TEMPER is built for what comes next: precision chemistry for stability and potency, plus targeting approaches that carry siRNA into muscle, heart, CNS and other extrahepatic tissues. We designed it so that siRNA delivery is no longer the limit on which diseases our partners can pursue.”

The introduction of TEMPER expands Alloy’s existing Genetic Medicines division, which provides drug discovery and preclinical development services focused on RNA-based treatments.

The company’s portfolio already includes its AntiClastic platform for antisense oligonucleotides, another class of RNA-targeting molecules designed to modify or reduce the production of disease-related proteins.

Alloy also develops antibody-oligonucleotide conjugates and antibody discovery technologies intended to improve the precision of drug delivery.

By adding TEMPER, the company aims to provide biotechnology and pharmaceutical partners with a broader range of technologies for designing, optimizing, and evaluating RNA therapeutics.

The platform is intended to support multiple stages of early drug development, from molecular design and delivery optimization to experimental evaluation in preclinical models.

Alloy plans to continue developing the technology through internal research and strategic collaborations.

The company has not announced clinical trial results for TEMPER, and its ability to deliver effective treatments to tissues beyond the liver remains to be established through further research.

The launch reflects growing interest in expanding RNA therapeutics beyond their established applications and developing delivery technologies capable of targeting a wider range of diseases.

Leave A Reply

Please enter your comment!
Please enter your name here